Savara Inc
SVRA evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $1.11B
- Lead Asset:
- molbreevi (Phase 3)
What it means
What to watch
Prepared research question
What matters most for SVRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SVRA
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, with its sole program, molgramostim inhalation solution (MOLBREEVI), in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and under regulatory review in the U.S., EU, and UK.
Key risk: Single product dependency
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.11B
Cash Runway
—
Lead Asset
molbreevi (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials for Savara Inc.
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, with its sole program, molgramostim inhalation solution (MOLBREEVI), in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and under regulatory review in the U.S., EU, and UK.
- Savara's sole program is molgramostim inhalation solution (MOLBREEVI), an inhaled GM-CSF biologic in Phase 3 for autoimmune PAP [sec_mda · as of 2026-03-13].
- The FDA is reviewing the MOLBREEVI BLA under Priority Review with an Action Date of November 22, 2026 [sec · filed 2026-04-24].
- Marketing applications are also under review in the EU (decision expected Q1 2027) and UK (decision expected Q4 2026) [sec · filed 2026-04-24].
- As of June 30, 2026, Savara reported cash & equivalents of $41.8M, net income of -$40.2M, and shareholders' equity of $143.7M [sec].
- The company has never generated product revenue and incurred a net loss of $118.8M in 2025 [sec_mda · as of 2026-03-13].
What works
- MOLBREEVI has received Priority Review from the FDA, indicating the agency's recognition of its potential to address a significant unmet need [sec · filed 2026-04-24].
- The company has a long-term supply agreement with PARI Pharma GmbH for the proprietary eFlow® nebulizer system, a key delivery technology [pipeline].
- Positive topline results from the Phase 3 IMPALA-2 trial have been announced, supporting regulatory submissions [sec_mda · as of 2026-03-13].
What to weigh
- Savara has never been profitable and has incurred operating losses each year since inception, with an accumulated deficit of $608.1M as of December 31, 2025 [sec_mda · as of 2026-03-13].
- The company is substantially dependent on the clinical, regulatory, and commercial success of a single product candidate, MOLBREEVI [sec_mda · as of 2026-03-13].
- Cash and equivalents declined from $235.7M at December 31, 2025 to $41.8M as of June 30, 2026, reflecting high cash burn [sec_mda · as of 2026-03-13] [sec].
- The BLA for MOLBREEVI previously received a Refusal to File letter, which was resolved by resubmission in December 2025 [sec_mda · as of 2026-03-13].
From the filings
Quoted directly from source documents.
MOLBREEVI is the sole program and is in Phase 3 for autoimmune PAP
“Our sole program, molgramostim inhalation solution ("MOLBREEVI " or "molgramostim" ) , is an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor ("GM-CSF") in Phase 3 development for autoimmune pulmonary alveolar proteinosis ("autoimmune PAP").”
SEC MD&A · March 13, 2026
FDA Action Date for MOLBREEVI BLA is November 22, 2026
“The U.S. Food & Drug Administration (FDA) is reviewing the MOLBREEVI Biologics License Application under Priority Review, with an Action Date of November 22, 2026.”
SEC filings · April 24, 2026
Company has never been profitable and has accumulated deficit
“We have never been profitable and have incurred operating losses in each year since inception. Our net losses were $118.8 million and $95.9 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $608.1 million.”
SEC MD&A · March 13, 2026
Catalyst timeline
- 2025-10-22 · Phase 3 pediatric study start — An open-label, multicenter clinical study to evaluate efficacy and safety of inhaled molgramostim in pediatric patients with autoimmune PAP.
Risks & what to watch (4)›
Key risks
- Single product dependency — Savara is substantially dependent on the clinical, regulatory, and commercial success of MOLBREEVI [sec_mda · as of 2026-03-13].
- No revenue and high cash burn — No product revenue generated; cash declined from $235.7M (Dec 2025) to $41.8M (Jun 2026) [sec_mda · as of 2026-03-13] [sec].
- Regulatory setbacks possible — BLA previously received a Refusal to File letter; future approvals not guaranteed [sec_mda · as of 2026-03-13].
- Accumulated deficit — Accumulated deficit of $608.1M as of Dec 31, 2025, with ongoing net losses [sec_mda · as of 2026-03-13].
What to watch
- FDA action on MOLBREEVI BLA by November 22, 2026 [sec · filed 2026-04-24].
- UK MHRA decision on MOLBREEVI MAA expected in Q4 2026 [sec · filed 2026-04-24].
- EU decision on MOLBREEVI MAA expected in Q1 2027 [sec · filed 2026-04-24].
- Cash runway and potential need for additional financing given declining cash reserves [sec].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Savara Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Savara Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.34 · 0% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
186
Total value held
$1.15B
| Holder | Shares | Value |
|---|---|---|
| nea management company, llc | 24,471,264 | $133.6M |
| bain capital life sciences investors, llc | 17,600,621 | $96.1M |
| venrock adviser, llc | 13,740,375 | $75.0M |
| deerfield management company, l.p. | 13,569,000 | $74.1M |
| tcg crossover management, llc | 12,362,205 | $67.5M |
| blackrock, inc. | 11,291,185 | $61.6M |
| frazier life sciences management, l.p. | 9,720,852 | $53.1M |
| polar capital holdings plc | 9,541,786 | $52.1M |
| vanguard capital management llc | 7,783,913 | $42.5M |
| nantahala capital management, llc | 7,344,783 | $40.1M |
Showing top 10 of 186 institutional holders of Savara Inc. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 15.6%
- Days to cover
- 15.0
- Shares short
- 27,429,578
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SVRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Savara Inc?
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, with its sole program, molgramostim inhalation solution (MOLBREEVI), in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and under regulatory review in the U.S., EU, and UK.
What is Savara Inc's lead drug candidate?
Savara Inc's most advanced tracked candidate is molbreevi (Phase 3) for autoimmune pulmonary alveolar proteinosis (aPAP).
Who is the CEO of Savara Inc?
Mr. Matthew Pauls J.D., M.B.A. is the chief executive officer of Savara Inc (SVRA).
Where is Savara Inc headquartered?
Savara Inc (SVRA) is headquartered in Yardley, PA, United States.
What therapeutic areas does Savara Inc focus on?
Savara Inc develops therapies across Immunology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.